Bayer's Actron OTC ketoprofen set to launch "within weeks".
This article was originally published in The Tan Sheet
Executive Summary
BAYER'S ACTRON OTC KETOPROFEN LAUNCH COMING "WITHIN WEEKS," the company said, following FDA's Oct. 6 approval of the 12.5 mg strength of the NSAID for OTC analgesic indications. Calling Actron "extremely important" to the company and promising a "formidable launch," Bayer said it intends to support its new Rx-to-OTC switch with major promotional campaigns directed at consumers, physicians and pharmacists.
You may also be interested in...
Second Time Lucky? Sumatriptan One Of Three Switches On The Cards In Germany
A second attempt at switching sumatriptan for migraines, as well as switch applications for non-steroidal anti-inflammatories ketoprofen and liquid ibuprofen, are all on the agenda at Germany's next Expert Committee for Prescription meeting in June.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands